trending Market Intelligence /marketintelligence/en/news-insights/trending/8ubktros54jlly9nksofjq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

WuXi AppTec gets IPO nod for Shanghai Stock Exchange

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

WuXi AppTec gets IPO nod for Shanghai Stock Exchange

China Securities Regulatory Commission gave permission to Shanghai-based WuXi AppTec Inc. to list on the Shanghai Stock Exchange, South China Morning Post reported.

The regulatory approval took only seven weeks.

The contract research organization is looking to raise about 5.7 billion Chinese yuan through issuing 104.2 million shares, according to its IPO prospectus released in February. It plans to use the funds to expand its facilities and research capabilities.

Formerly known as WuXi PharmaTech Inc., the company was privatized in 2015 in a $3.3 billion merger deal with Wuxi Merger Ltd., a wholly-own subsidiary of New WuXi Life Science Ltd.

The former entity delisted from the New York Stock Exchange in December 2015.

As of March 27, US$1 was equivalent to 6.28 yuan.